Who
Jennifer Lew
Director
Company insider
Files Form 4 as: Director, Boundless Bio; EVP & Chief Financial Officer, Annexon; Chief Financial Officer, Aduro Biotech; VP, Finance & PAO, Dynavax Technologies.
In numbers
- Trades disclosed
- 125
- Buys
- 2
- Sells
- 32
- Bought
- $68K
- Sold
- $2.2M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 19 Feb 2010
- Last trade
- 15 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 15 Jun 2026 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 15 Jun 2026filed 15 Jun 2026 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $30K5,565 at $5.42 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $30K5,565 at $5.42 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ANNX AnnexonBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ANNX AnnexonBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $40K7,851 at $5.11 | filing |
| 18 Feb 2026filed 20 Feb 2026 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $40K7,851 at $5.11 | filing |
| 14 Jul 2025filed 16 Jul 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $2,8821,117 at $2.58 | filing |
| 23 Jun 2025filed 23 Jun 2025 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 27 Feb 2025filed 3 Mar 2025 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —272,575 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $20K6,912 at $2.92 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $5,3221,786 at $2.98 | filing |
| 15 Jul 2024filed 17 Jul 2024 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $6,6571,104 at $6.03 | filing |
| 27 Mar 2024filed 29 Mar 2024 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —13,219 at $0.00 | filing |
| 27 Feb 2024filed 3 Mar 2025 | ANNX AnnexonBiotechnology | SEC FORM 4 Code A | —44,963 at $0.00 | filing |
| 20 Feb 2024filed 21 Feb 2024 | ANNX AnnexonBiotechnology | SEC FORM 4 Sold | $14K2,593 at $5.53 | filing |
| 16 Feb 2024filed 21 Feb 2024 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.